Peritoneal Neoplasms
Recent clinical, regulatory, research and industry developments relating to this disease.
Analysis of real world FRα testing in ovarian, fallopian tube, and primary peritoneal cancers.
Heterogeneity of claudin 18.2 expression in metastatic gastric cancer.
Peritoneal Metastatic Gastric Cancer: Local Treatment Options and Recommendations.
FIGO staging of endometrial cancer: 2023.
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022.
Staging classification for cancer of the ovary, fallopian tube, and peritoneum.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 3 clinical trials expected to report results, the earliest in Q4 2026.
- Q4 2026A Multicenter Phase 3, Double-Blind, Placebo-Controlled Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin- Oregovomab) vs Chemotherapy (Paclitaxel-Carboplatin- Placebo) in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma
- Q3 2027MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer: a Randomized Double-blinded Placebo-controlled Multi-centre Phase III Trial (ENGOT-ov54/Swiss-GO-2/MATAO), Including LOGOS (Low Grade Ovarian Cancer Sub-study).
- Q4 2028FRAmework-01: A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) Versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan Plus Bevacizumab Versus Platinum-Based Chemotherapy Plus Bevacizumab in Platinum-Sensitive Ovarian Cancer.
Clinical MilestonesViewHide
- 2026-07-07FRAmework-01: A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) Versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan Plus Bevacizumab Versus Platinum-Based Chemotherapy Plus Bevacizumab in Platinum-Sensitive Ovarian Cancer.Results expected Q4 2028
- 2026-04-01A Multicenter Phase 3, Double-Blind, Placebo-Controlled Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin- Oregovomab) vs Chemotherapy (Paclitaxel-Carboplatin- Placebo) in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal CarcinomaResults expected Q4 2026
- 2025-09-29MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer: a Randomized Double-blinded Placebo-controlled Multi-centre Phase III Trial (ENGOT-ov54/Swiss-GO-2/MATAO), Including LOGOS (Low Grade Ovarian Cancer Sub-study).Results expected Q3 2027
- 2026-08-01ClinicalAn Open-label, Global, Multi-Arm Study to Evaluate the Efficacy and Safety of Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers (BELLA)Primary completion
- 2026-07-07ClinicalFRAmework-01: A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) Versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan Plus Bevacizumab Versus Platinum-Based Chemotherapy Plus Bevacizumab in Platinum-Sensitive Ovarian Cancer.Results expected Q4 2028
- 2026-05-04ClinicalA Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (KEYLYNK-001 / ENGOT-ov43 / GOG-3036)Results posted
- 2026-04-01ClinicalA Multicenter Phase 3, Double-Blind, Placebo-Controlled Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin- Oregovomab) vs Chemotherapy (Paclitaxel-Carboplatin- Placebo) in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal CarcinomaResults expected Q4 2026
- 2025-09-29ClinicalMAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer: a Randomized Double-blinded Placebo-controlled Multi-centre Phase III Trial (ENGOT-ov54/Swiss-GO-2/MATAO), Including LOGOS (Low Grade Ovarian Cancer Sub-study).Results expected Q3 2027
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Peritoneal Neoplasms5
- Hyperthermia, Induced2
- Ovarian Neoplasms2
- Stomach Neoplasms2
- Carcinoma, Endometrioid1
- Carcinoma, Ovarian Epithelial1
- Claudins1
- Colorectal Neoplasms1
Leading journals6
- International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics2
- Annals of surgical oncology1
- Current oncology (Toronto, Ont.)1
- Gynecologic oncology1
- Journal of the National Comprehensive Cancer Network : JNCCN1
- Scientific reports1
Leading researchers8
- Acs M1
- Alvarez RD1
- Armetta J1
- Armstrong DK1
- Backes FJ1
- Bakkum-Gamez JN1
- Barroilhet L1
- Behbakht K1
Affiliations (unnormalised)6
- Abramson Cancer Center at the University of Pennsylvania.1
- Asan Medical Center1
- Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute.1
- Catharina Cancer Institute1
- Centre Hospitalier Lyon-sud1
- CICLY: Center for Innovation in Cancer in Lyon1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Peritoneal neoplasms are tumors or cancers arising in the peritoneum. The literature grounding here also includes secondary peritoneal disease, particularly peritoneal metastasis from gastric cancer.
The supplied grounding supports secondary involvement of the peritoneum from advanced gastric cancer as a cause of peritoneal neoplastic disease. No primary etiologic causes are specified.
The grounding indicates that peritoneal neoplasms can occur as secondary peritoneal metastasis, meaning malignant spread to the peritoneum from another primary cancer such as gastric cancer. The literature also frames this as a disease process addressed by local and intraperitoneal treatment approaches, but it does not provide a deeper biological mechanism.
Advanced gastric cancer is associated with peritoneal metastasis in the supplied review abstract. No additional risk factors are specified in the grounding.
The grounding supports systemic chemotherapy as a baseline treatment for peritoneal metastatic gastric cancer. It also describes additive local modalities used in selected patients, including cytoreductive surgery and intraperitoneal chemotherapy, with approaches such as HIPEC, NIPS, and PIPAC used in multimodal treatment concepts for curative or palliative intent.
AI-generated summary grounded in MeSH and 1 peer-reviewed source. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Tumors or cancer of the PERITONEUM.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.